CN1304000C - 缬沙坦在制备用于治疗肺癌的药物中的用途 - Google Patents

缬沙坦在制备用于治疗肺癌的药物中的用途 Download PDF

Info

Publication number
CN1304000C
CN1304000C CNB998150452A CN99815045A CN1304000C CN 1304000 C CN1304000 C CN 1304000C CN B998150452 A CNB998150452 A CN B998150452A CN 99815045 A CN99815045 A CN 99815045A CN 1304000 C CN1304000 C CN 1304000C
Authority
CN
China
Prior art keywords
receptors
receptor
valsartan
lung
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998150452A
Other languages
English (en)
Chinese (zh)
Other versions
CN1331590A (zh
Inventor
G·R·布洛克
M·德加斯帕罗
S·M·甘特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1304000(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1331590A publication Critical patent/CN1331590A/zh
Application granted granted Critical
Publication of CN1304000C publication Critical patent/CN1304000C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB998150452A 1998-12-23 1999-12-22 缬沙坦在制备用于治疗肺癌的药物中的用途 Expired - Fee Related CN1304000C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98811258.7 1998-12-23
EP98811257 1998-12-23
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
EP98811257.9 1998-12-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200410087973XA Division CN1636561A (zh) 1998-12-23 1999-12-22 At－1受体拮抗剂在治疗与at－1受体增加有关的疾病中的应用

Publications (2)

Publication Number Publication Date
CN1331590A CN1331590A (zh) 2002-01-16
CN1304000C true CN1304000C (zh) 2007-03-14

Family

ID=26152118

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998150452A Expired - Fee Related CN1304000C (zh) 1998-12-23 1999-12-22 缬沙坦在制备用于治疗肺癌的药物中的用途
CNA200410087973XA Pending CN1636561A (zh) 1998-12-23 1999-12-22 At－1受体拮抗剂在治疗与at－1受体增加有关的疾病中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200410087973XA Pending CN1636561A (zh) 1998-12-23 1999-12-22 At－1受体拮抗剂在治疗与at－1受体增加有关的疾病中的应用

Country Status (26)

Country Link
EP (3) EP2298298A3 (https=)
JP (2) JP2002533390A (https=)
KR (1) KR100646716B1 (https=)
CN (2) CN1304000C (https=)
AT (2) ATE524176T1 (https=)
AU (4) AU3043000A (https=)
BR (1) BR9916576A (https=)
CA (2) CA2351357A1 (https=)
CY (2) CY1106581T1 (https=)
CZ (2) CZ297795B6 (https=)
DE (1) DE69935249T2 (https=)
DK (2) DK1588706T3 (https=)
ES (2) ES2373556T3 (https=)
HK (1) HK1038888B (https=)
HU (1) HUP0104780A3 (https=)
ID (1) ID29856A (https=)
IL (5) IL143233A0 (https=)
NO (2) NO328775B1 (https=)
NZ (3) NZ587909A (https=)
PL (1) PL199100B1 (https=)
PT (2) PT1140071E (https=)
RU (3) RU2271809C2 (https=)
SI (2) SI1588706T1 (https=)
SK (1) SK9132001A3 (https=)
TR (7) TR200200764T2 (https=)
WO (1) WO2000038676A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
JPWO2002083127A1 (ja) * 2001-04-09 2004-09-30 宮田　敏男 蛋白修飾物生成抑制組成物
CN1529697B (zh) 2001-05-31 2010-09-22 维科尔药物公司 用作血管紧张素ⅱ激动剂的三环化合物
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2005041941A2 (en) * 2003-11-03 2005-05-12 Zentiva, A.S. Valsartan containing formulation
DK2033629T3 (da) 2004-12-24 2013-02-04 Krka Fast farmaceutisk sammensætning omfattende valsartan
WO2006066361A1 (en) * 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2008120242A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
CN101888829A (zh) 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
NZ584686A (en) * 2007-11-06 2013-03-28 Novartis Ag Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
US20110104166A1 (en) 2008-01-18 2011-05-05 Stankovic Konstantina M Methods and Compositions for Treating Polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
US5338744A (en) * 1990-10-02 1994-08-16 Warner-Lambert Company Angiotensin II antagonists used to treat reproductive functions associated with AT2 receptors
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
US5399575A (en) * 1990-12-01 1995-03-21 Boehringer Mannheim Gmbh Pyridine compounds which have useful pharmaceutical activity
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN1129702A (zh) * 1994-09-15 1996-08-28 默克专利股份有限公司 咪唑并吡啶
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
CN1146765A (zh) * 1994-03-04 1997-04-02 鲁索-艾克勒夫公司 咪唑衍生物在治疗与血管紧张肽at1及at2受体有关疾病方面的应用，某些这样的化合物，它们的制法，它们作为医药的应用以及含有它们的药物组合物
WO1997031634A1 (en) * 1996-02-29 1997-09-04 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
US5683997A (en) * 1992-12-11 1997-11-04 Ciba-Geigy Corporation Substituted benzazepinones

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
DK0403159T3 (da) 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (https=) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
AU675935B2 (en) 1992-04-13 1997-02-27 Astrazeneca Ab Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
AU685768B2 (en) 1992-12-11 1998-01-29 Novartis Ag Benzazepinone derivatives
HUT76542A (en) 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
AU7213296A (en) 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU2316997A (en) 1996-02-27 1997-09-16 David H Thompson Liposomal delivery system
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
TR200100062T2 (tr) 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
IL144216A0 (en) * 1999-01-26 2002-05-23 Novartis Ag Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338744A (en) * 1990-10-02 1994-08-16 Warner-Lambert Company Angiotensin II antagonists used to treat reproductive functions associated with AT2 receptors
US5399575A (en) * 1990-12-01 1995-03-21 Boehringer Mannheim Gmbh Pyridine compounds which have useful pharmaceutical activity
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
US5683997A (en) * 1992-12-11 1997-11-04 Ciba-Geigy Corporation Substituted benzazepinones
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
CN1146765A (zh) * 1994-03-04 1997-04-02 鲁索-艾克勒夫公司 咪唑衍生物在治疗与血管紧张肽at1及at2受体有关疾病方面的应用，某些这样的化合物，它们的制法，它们作为医药的应用以及含有它们的药物组合物
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN1129702A (zh) * 1994-09-15 1996-08-28 默克专利股份有限公司 咪唑并吡啶
WO1997031634A1 (en) * 1996-02-29 1997-09-04 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis

Also Published As

Publication number Publication date
TR200605471T2 (tr) 2006-11-21
WO2000038676A1 (en) 2000-07-06
CA2351357A1 (en) 2000-07-06
EP1588706B1 (en) 2011-09-14
NO328775B1 (no) 2010-05-10
PT1140071E (pt) 2007-05-31
TR200805741T2 (tr) 2008-10-21
AU2006203077B2 (en) 2009-10-08
AU2003266433A1 (en) 2004-01-08
TR200605472T1 (tr) 2007-02-21
TR200805740T1 (tr) 2010-06-21
RU2361575C2 (ru) 2009-07-20
ATE354364T1 (de) 2007-03-15
EP1140071B1 (en) 2007-02-21
DE69935249D1 (de) 2007-04-05
ES2373556T3 (es) 2012-02-06
SK9132001A3 (en) 2002-01-07
NO20100041L (no) 2001-08-16
HK1038888A1 (en) 2002-04-04
EP1588706A3 (en) 2005-12-07
PT1588706E (pt) 2011-12-21
CY1112395T1 (el) 2015-12-09
CY1106581T1 (el) 2012-01-25
DK1588706T3 (da) 2012-01-16
JP5254258B2 (ja) 2013-08-07
EP1140071A1 (en) 2001-10-10
SI1140071T1 (sl) 2007-08-31
ID29856A (id) 2001-10-18
TR200200764T2 (tr) 2002-07-22
HK1038888B (en) 2007-09-21
NZ553010A (en) 2008-09-26
EP2298298A3 (en) 2011-05-11
CZ297795B6 (cs) 2007-03-28
ATE524176T1 (de) 2011-09-15
DE69935249T2 (de) 2007-10-31
RU2005124363A (ru) 2007-02-10
DK1140071T3 (da) 2007-06-04
KR20010089681A (ko) 2001-10-08
RU2271809C2 (ru) 2006-03-20
TR200805275T2 (tr) 2008-09-22
NZ511938A (en) 2004-02-27
KR100646716B1 (ko) 2006-11-17
CZ20012306A3 (cs) 2001-12-12
HUP0104780A2 (hu) 2002-04-29
PL349424A1 (en) 2002-07-29
CA2622805C (en) 2011-05-10
EP1588706A2 (en) 2005-10-26
IL179015A0 (en) 2007-03-08
IL143233A0 (en) 2002-04-21
ES2281978T3 (es) 2007-10-01
AU2009220022B2 (en) 2011-11-03
RU2008143545A (ru) 2010-05-10
SI1588706T1 (sl) 2012-01-31
IL179017A0 (en) 2007-03-08
IL179016A0 (en) 2007-03-08
TR200101784T2 (tr) 2001-10-22
JP2002533390A (ja) 2002-10-08
AU3043000A (en) 2000-07-31
NO20013143D0 (no) 2001-06-22
NZ587909A (en) 2012-05-25
CN1636561A (zh) 2005-07-13
AU2006203077A1 (en) 2006-08-10
JP2010090169A (ja) 2010-04-22
HUP0104780A3 (en) 2002-11-28
AU2003266433B2 (en) 2006-08-10
AU2009220022A1 (en) 2009-10-15
CZ293257B6 (cs) 2004-03-17
EP2298298A2 (en) 2011-03-23
IL143233A (en) 2007-07-24
CA2622805A1 (en) 2000-07-06
PL199100B1 (pl) 2008-08-29
CN1331590A (zh) 2002-01-16
BR9916576A (pt) 2001-10-02
NO20013143L (no) 2001-08-16

Similar Documents

Publication Publication Date Title
CN1304000C (zh) 缬沙坦在制备用于治疗肺癌的药物中的用途
US20120010258A1 (en) Additional therapeutic use
JP2024001219A (ja) 治療活性化合物の医薬組成物
TW202308640A (zh) 索托拉西布配製物
EP1013273A1 (en) Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
CN1878548A (zh) AT1拮抗物、阿米洛利或triameterine与一种利尿剂的组合
TW202245786A (zh) 喹唑啉化合物及藥物組合物的應用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070314

Termination date: 20141222

EXPY Termination of patent right or utility model